Anti-desmoplakin antibodies in erythema multiforme and Stevens-Johnson syndrome sera: Pathogenic or epiphenomenon?

European Journal of Dermatology

Volumn 21, Issue 1, 2011, Pages 32-36

  Cozzani, Emanuele ^a   di Zenzo, Giovanni ^b   Calabresi, Valentina ^b   Caproni, Marzia ^c   Schena, Donatella ^d   Quaglino, Pietro ^e   Marzano, Angelo V ^f   Fabbri, Paolo ^c   Rebora, Alfredo ^a   Parodi, Aurora ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoantibodies; Desmoplakins; Erythema multiforme; Immunoblotting; Immunofluorescence; Pathogenesis

Indexed keywords

DESMOPLAKIN; DESMOPLAKIN I; DESMOPLAKIN I ANTIBODY; DESMOPLAKIN II; DESMOPLAKIN II ANTIBODY; MONOCLONAL ANTIBODY; POLYPEPTIDE; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; PEPTIDE;

ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN RECOGNITION; ARTICLE; CELL LABELING; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHEMA MULTIFORME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOPRECIPITATION; ISOTOPE LABELING; KERATINOCYTE; MOLECULAR WEIGHT; NONHUMAN; PROTEIN DENATURATION; PROTEIN TRANSPORT; RAT; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANTIBODIES, ANTI-IDIOTYPIC; DESMOPLAKINS; ERYTHEMA MULTIFORME; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; KERATINOCYTES; PEPTIDES; STEVENS-JOHNSON SYNDROME;

EID: 79957502073     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2010.1150     Document Type: Article

References (21)

1. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnosis criteria, and causes. J Am Acad Dermatol 1983; 8: 763-75.
2. Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol 2010; 62: 45-53.
3. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-9.
4. Fritsch P. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome. Eur J Dermatol 2008; 18: 216-7.
5. Margolis RJ, Tonnesen MG, Harrist TJ, et al. Lymphocyte subsets and Langerhans cells/indeterminate cells in erythema multiforme. J Invest Dermatol 1983; 81: 403-6.
6. Tonnesen MG, Harrist TJ, Wintroub BU, et al. Erythema multiforme: microvascular damage and infiltration of lymphocytes and basophils. J Invest Dermatol 1983; 80: 282-6.
7. Foedinger D, Anhalt GJ, Boecskoer B, et al. Autoantibodies to desmoplakin I and II in patients with erythema multiforme. J Exp Med 1995; 181: 169-79.
8. Foedinger D, Sterniczky B, Elbe A, et al. Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. J Invest Dermatol 1996; 106: 1012-6.
9. Foedinger D, Elbe-Burger A, Sterniczky B, et al. Erythema multiforme associated human autoantibodies against desmoplakin I and II: biochemical characterization and passive transfer studies into newborn mice. J Invest Dermatol 1998; 111: 503-10.
10. Hinterhuber G, Binder M, Marquardt Y, et al. Enzymelinked immunosorbent assay for detection of peptide-specific human antidesmoplakin autoantibodies. Br J Dermatol 2005; 153: 413-6.
11. Fukiwake N, Moroi Y, Urabe K, et al. Detection of autoantibodies to desmoplakin in a patient with oral erythema multiforme. Eur J Dermatol 2007; 17: 238-41.
12. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-35.
13. Cozzani E, Dal Bello MG, Mastrogiacomo A, et al. Antidesmoplakin antibodies in pemphigus vulgaris. Br J Dermatol 2006; 154: 624-8.
14. Park GT, Quan G, Lee JB. Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin. Br J Dermatol 2006; 155: 337-43.
15. Hodge L, Black MM, Ramnarain N, Bhogal B. Indirect complement immunofluorescence in the immunopathological assessment of bullous pemphigoid, cicatricial pemphigoid, and herpes gestationis. Clin Exp Dermatol 1978; 3: 61-7.
16. Cozzani E, Kanitakis J, Nicolas JF, et al. Comparative study of indirect immunofluorescence and immunoblotting for the diagnosis of autoimmune pemphigus. Arch Dermatol Res 1994; 286: 295-9.
17. Cauza K, Hinterhuber G, Mann U, et al. Internalization via plasmalemmal vesicles: a route for antidesmoplakin autoantibodies into cultured human keratinocytes. Exp Dermatol 2003; 12: 546-54.
18. Johnson SM, Smoller BR, Horn TD. Erythema multiforme associated human autoantibodies against desmoplakin I and II. J Invest Dermatol 1999; 112: 395-6.
19. Bhol KC, Colon JE, Ahmed AR. Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human beta4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model. J Invest Dermatol 2003; 120: 701-2.
20. Kiss M, Husz S, Jánossy T, et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005; 24: 1-10.
21. Di Zenzo G, Calabresi V, Olasz EB, et al. Sequential intramolecular epitope spreading of humoral responses to human BPAG2 in a transgenic model. J Invest Dermatol 2010; 130: 1040-7.